Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone913-353-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.57 million
Profitability
Miscellaneous
Employees85
OptionableOptionable
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analysts' expectations of $5.70 million. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%. View Aratana Therapeutics' Earnings History.
When is Aratana Therapeutics' next earnings date?
What price target have analysts set for PETX?
5 Wall Street analysts have issued 12-month target prices for Aratana Therapeutics' stock. Their predictions range from $4.14 to $10.00. On average, they expect Aratana Therapeutics' stock price to reach $7.0280 in the next twelve months. This suggests a possible upside of 59.0% from the stock's current price. View Analyst Price Targets for Aratana Therapeutics.
What is the consensus analysts' recommendation for Aratana Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aratana Therapeutics.
Has Aratana Therapeutics been receiving favorable news coverage?
News headlines about PETX stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aratana Therapeutics earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Athenex (ATNX), ImmunoGen (IMGN), CytomX Therapeutics (CTMX), Radius Health (RDUS), Apellis Pharmaceuticals (APLS), G1 Therapeutics (GTHX), Arvinas (ARVN), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Inflarx (IFRX), Evolus (EOLS), ANI Pharmaceuticals (ANIP), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Principia Biopharma (PRNB).
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Mr. Craig A. Tooman, Pres, CEO, CFO, Treasurer & Director (Age 53)
- Dr. Ernst Heinen, Chief Devel. Officer (Age 56)
- Mr. John Paolucci, Director of Marketing
- Mr. Brent A. Standridge, Consultant (Age 61)
- Mr. John C. Ayres J.D., Gen. Counsel & Sec.
Who are Aratana Therapeutics' major shareholders?
Aratana Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.46%), Engaged Capital LLC (7.17%), General American Investors Co. Inc. (3.29%), Massachusetts Financial Services Co. MA (3.08%), Dimensional Fund Advisors LP (2.54%) and Millennium Management LLC (1.32%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.
Which institutional investors are selling Aratana Therapeutics stock?
PETX stock was sold by a variety of institutional investors in the last quarter, including Engaged Capital LLC, General American Investors Co. Inc., NJ State Employees Deferred Compensation Plan, MetLife Investment Advisors LLC, Principal Financial Group Inc., Weiss Multi Strategy Advisers LLC and Stifel Financial Corp. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.
Which institutional investors are buying Aratana Therapeutics stock?
PETX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Assenagon Asset Management S.A., BlackRock Inc., State Board of Administration of Florida Retirement System, Dimensional Fund Advisors LP, Geode Capital Management LLC, Alambic Investment Management L.P. and Acadian Asset Management LLC. View Insider Buying and Selling for Aratana Therapeutics.
How do I buy shares of Aratana Therapeutics?
Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aratana Therapeutics' stock price today?
One share of PETX stock can currently be purchased for approximately $4.42.
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $214.92 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.
What is Aratana Therapeutics' official website?
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
